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Abstract: COPD exerts a substantial burden on health and health care systems globally and 
will continue to do so for the foreseeable future. Treatment however can be costly and health 
care providers are interested in both whether treatments can offer improvements in disease 
burden and whether they represent value for money. Economic evaluations seek to resolve this 
issue by producing results that can be used to inform and assist the decision maker in allocat-
ing scarce health care resources. In this paper we introduce economic evaluation and then use 
these themes to review and critically appraise the existing COPD economic evaluations, in 
order to assess quality in light of today’s standards. The use of existing economic evaluations 
in informing the decision maker is then discussed. Ten out of the ﬁ  fteen studies were clinical 
trial or observational study based, and the remaining ﬁ  ve on a decision analytic model. Study 
design, interventions, outcome measures and the use of uncertainty varied considerably; con-
sequentially the results are difﬁ  cult to compare in any consistent manner. Efforts for future 
studies to harmonize study design and methodology, particularly towards adopting a model-
ing framework, using current treatment as comparator and adopting a common effectiveness 
measure, such as the QALY, should be made in order to produce results that are comparable 
and useful to a decision maker.
Keywords: COPD, burden of disease, economic evaluation, cost effectiveness, pharmaco-
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Introduction
COPD is deﬁ  ned by the Global Initiative for Chronic Obstructive Lung Disease 
(GOLD) as:
“…a preventable and treatable disease…characterised by airﬂ  ow limitation that is not 
fully reversible. The airﬂ  ow limitation is usually progressive and associated with an 
abnormal inﬂ  ammatory response of the lung to noxious particles or gases.” (GOLD 
2006)
COPD is a major cause of morbidity and mortality worldwide and is the only major 
cause of morbidity that is increasing. In the US, the death rate for COPD doubled 
between 1970 and 2002 whilst that for all other major causes either decreased or 
stagnated (Jemal et al 2005). A substantial increase in the global burden of COPD is 
therefore expected for the future.
Against this backdrop, there is increasing interest in potential treatments for COPD, 
in particular the use of pharmacotherapy. The aim of current pharmacotherapy, in the 
absence of a disease cure, is to prevent and control symptoms, reduce the frequency 
and severity of exacerbations, improve health status and improve exercise tolerance 
(GOLD 2006). There are numerous treatments available for COPD and these are 
illustrated in Table 1 below together with current treatment guidelines for the manage-
ment of the disease. Treatment is dependent upon disease severity; classiﬁ  ed here in International Journal of COPD 2008:3(1) 72
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terms of the GOLD guidelines, with four states from mild 
through to very severe. Disease management is additive; as 
the disease progresses through the stages, more treatments 
are added as shown in Table 1 and because COPD is progres-
sive, treatment must be continuous throughout the lifetime 
of the patient.
New treatments can be costly, however, and health care 
providers are increasingly interested not only in whether 
treatments can offer improvements in disease burden, but also 
whether they offer value for money. Economic evaluation 
aims to establish the value of a new treatment by bringing 
together available evidence on the efﬁ  cacy, effectiveness and 
costs of that drug compared to an alternative management 
strategy, such as an existing treatment.
In order to set the scene for the pharmacoeconomics in 
COPD, the ﬁ  rst section describes the burden of illness and 
ﬁ  nancial costs associated with COPD. The second section 
presents a review and critical appraisal of the published phar-
macoeconomic literature in COPD. Finally, the use of existing 
economic evaluations in informing and assisting the decision 
maker to allocate scarce health care resources is discussed.
Burden of COPD
This section reviews the health burden of COPD – mortality, 
morbidity, the effects of age, gender and smoking – and the 
ﬁ  nancial burden, with particular emphasis on the key driv-
ers of cost; disease severity and exacerbation frequency and 
severity.
Health burden
Morbidity and mortality
Current estimates of the prevalence of COPD in the gen-
eral population in Europe are within the range of 4%–10% 
(European Respiratory Society and European Lung 
Foundation 2003). However actual rates of diagnosis are 
much lower, approximately 1% in the UK (Calverley and 
Bellamy 2000), and there is a wealth of evidence that suggests 
that COPD is heavily under diagnosed worldwide (Calverley 
and Bellamy 2000; Fukuchi et al 2004; Zielinski et al 2006). 
It is likely that a substantial number of people are unaware 
of having COPD (especially so in mild to moderate stages), 
and who, rather than seek help, may attribute problems such 
as breathlessness and fatigue to old age rather than on any 
underlying cause.
The World Health Organization (2000) found global 
COPD deaths to be the ﬁ  fth largest killer, accounting for 
4.5% of deaths worldwide (Murray Christopher et al 2001). 
The proportion of deaths for COPD varies between regions 
of the world: particularly concerning is the Western Paciﬁ  c 
region (including China, Malaysia, the Philippines and 
I) Mild II) Moderate III) Severe IV) Very severe
Classiﬁ  cation FEV1/FVC  0.70  FEV1 
 80% predicted
FEV1/FVC  0.70                   
50%  FEV1  80% 
predicted
FEV1/FVC  0.70                    
30% FEV1  50% 
predicted
FEV1/FVC  0.70 FEV1 30% predicted 
or FEV1  50% predicted plus chronic 
respiratory failure
Treatment Inﬂ  uenza vaccination
Short acting broncholdilator added when necessary:
1) Short acting β2 agonists: Fenoterol, Salbutamol, Terbutaline. 2) Short acting anticholinergic: Ipratropium.
Add rehabilitation. Add regular treatment with one or more long acting broncholdilators if needed: 
1) Long acting β2 agonists: Formoterol, Salmeterol. 2) Long acting anticholinergic: Tiotropium.
Add inhaled corticosteroids if exacerbations are repeated: Fluticasone, 
Beclomethasone, Triamcinolone, Budesonide.
Add long term oxygen if chronic respira-
tory failure. Consider surgical treatments: 
Lung volume reduction surgery; Lung 
transplantation; Bullectomy.
Note: This table has been adapted from the GOLD guidelines (GOLD 2006).
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Vietnam) where COPD accounts for 13.8% of all deaths and 
where COPD is ranked as the second leading cause of death, 
as shown in Table 2.
Age and gender
COPD increases with age and is a disease of the elderly. 
Data from both the US and the UK show that the prevalence 
of COPD is comparatively small among the under 45s but 
increases markedly throughout later years (US Department 
of Health and Human Services 2004). In the UK, about 1% 
of the general population is diagnosed with COPD increasing 
with age to around 5% of men between 65 and 74 and rising 
to 10% in men over 75 (Calverley and Bellamy 2000).
Gender speciﬁ  c mortality and prevalence for COPD 
seems to be country speciﬁ  c. In Canada and in Northern 
Europe, there is little difference between death rates by 
sex (European Respiratory Society and European Lung 
Foundation 2003). In other countries there are differ-
ences: mortality rates for Europe as a whole, suggest 
that two to three times as many men as women die from 
COPD (European Respiratory Society and European 
Lung Foundation 2003): many more men than women 
die of COPD in Eastern and Southern European countries 
(Zielinski et al 2006). In Singapore, female hospitalization 
and mortality from COPD is signiﬁ  cantly less than for male 
counterparts (Zielinski et al 2006). This difference is most 
probably attributable to historical reasons where smoking 
rates amongst men have been higher than for women. In 
recent years and in some countries, women now smoke as 
much as their male counterparts. Where smoking prevalence 
rates are equal—and have been for some time—we would 
expect to see similar mortality rates for COPD.
Smoking
COPD causes an accelerated depreciation of lung function 
over time compared with the average or predicted level for 
a healthy person, and is further accentuated by smoking. 
Calverley suggests that around 20% of smokers are suscep-
tible to some form of progressive lung disease (Calverley 
and Bellamy 2000), but it may be larger than this; Lokke 
reports that the absolute risk of developing COPD in smokers 
is at least 25% (Lokke et al 2006). In China where COPD 
represents a major public health problem, there is a huge 
population of smokers: 67% of men smoke (approximately 
300 million) (Mackay and Eriksen 2002). It is estimated that 
15% of people in China, who have ever smoked may have 
COPD (5% of never smokers) (Zielinski et al 2006).
As yet no pharmacological treatments have been found 
to alter this decline: only smoking cessation has been shown 
to effectively slow the deterioration in FEV1 and return the 
trajectory of lung function to one consistent with that of a 
non-smoker (Fletcher and Peto 1977). The Lung Health 
study, at ﬁ  ve years, found signiﬁ  cantly lower all-cause 
mortality rates in a ‘special intervention’ group where 
smoking cessation was actively encouraged, compared to 
the nonintervention group (Anthonisen et al 2005).
Financial burden
In the UK, total costs to the NHS for COPD have been 
estimated somewhere between £486 million (  = 719 
million) (Calverley and Sondhi 1998; Britton 2003) and 
£848 million (  = 1255 million ) (Guest 1999; Sullivan 
et al 2000) per year. Additionally, including some societal 
costs, most notably productivity costs (costs arising from 
loss of income through inability or absence from work), 
pushes total costs for COPD up to £982 million (  = 1453 
million) per year (Guest 1999; Britton 2003). Translating 
to a per patient cost of between £781(  = 1156) (Calverley 
and Sondhi 1998) and £1154 (  = 1708) per year (£1639
(  = 2425) when including societal costs). The major driv-
ers of this burden are disease severity and exacerbations. 
These are discussed below.
Drivers of cost
Disease severity
Costs increase substantially as disease severity moves from 
moderate to severe (with a much smaller increase between 
mild and moderate) (Britton 2003; Chapman et al 2003; 
Dal Negro et al 2003; Halpern et al 2003; Izquierdo 2003; 
Piperno et al 2003; Wouters 2003). Britton estimates that 
the direct costs of the three groups to be mild,  232 moder-
ate,  477 and severe,  2026. These values almost double 
with the inclusion of productivity costs (Britton 2003). As 
FEV1 deteriorates, a general shift from outpatient care to 
hospitalization, an increase in the use of oxygen therapy and 
Table 2 The burden of COPD – mortality
WHO region  Ranka % b
African 15  1.1
Americas 6  3.5
Eastern Mediterranean  15  1.4
European 5  2.8
South East Asia  9  2.2
Western Paciﬁ  c  2  13.8
aRanking for COPD deaths within region, compared to all other diseases/illnesses.
bPercentage of total deaths attributable to COPD in each region.International Journal of COPD 2008:3(1) 74
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a subsequent increase in total costs, especially in the most 
advanced stages of the disease has been shown to occur 
(Jansson et al 2002).
Exacerbations
Exacerbations are the leading driver of cost in COPD. A 
serious exacerbation will lead to hospitalization; indeed an 
exacerbation is the main reason why a COPD patient would 
attend hospital. COPD has been found to be the cause of 
approximately 90,000 hospital admissions within the UK 
alone and around 1 million hospital bed days per year 
(Lung and Asthma Information Agency 2003). The cost of 
exacerbations has been found to increase in line with the 
severity of exacerbations; a Swedish study reports: SEK 
120 (  = 13) for a mild, SEK 354 (  = 38) for mild/moder-
ate, SEK 2111 (  = 225) moderate and SEK 21,852 (  = 
2326) for a severe exacerbation. Exacerbations account for 
between 35%–40% of total health care costs (Andersson 
et al 2002). Hospitalizations as a proportion of total costs in 
other countries are also high; in the USA: 70.3% (Halpern 
et al 2003), Italy: 76.3% (Dal Negro et al 2003) and Spain: 
83.62% (Izquierdo 2003).
In the UK, the excess cost arising from acute exacerba-
tions has been estimated to be £45 million at 1994 prices (  = 
67 million) for a COPD population of 233,000 (McGuire 
et al 2001). Treatment which acts to reduce or prevent dis-
ease progression and or an exacerbation (particularly severe 
exacerbations) will have a direct effect on the total cost for 
COPD: in England and Wales, McGuire calculated that for 
every exacerbation related hospital admission avoided a total 
saving of approximately £1200 (  = 1776) would be made 
(McGuire et al 2001).
Productivity costs
Productivity costs are generally regarded as the cost of time 
off work due to illness. Productivity costs for COPD represent 
a signiﬁ  cant burden on society as COPD is a major cause of 
absenteeism from work (Britton 2003; Halpin 2006). People 
with COPD have a “substantially shortened’ work life com-
pared to the population average (Yelin et al 2006). Between 
1994 and 1995, it was estimated that 24 million lost work days 
were attributable to COPD within the UK alone (Calverley 
and Sondhi 1998). Within the 15 ‘original’ EU member states, 
COPD is estimated to account for 41 300 lost work days 
per 100 000 people and productivity losses of around  28.5 
billion per year. In Central and Eastern Europe, the number 
of lost work days is just 10% of this value; 4300 per 100 000 
people (European Respiratory Society and European Lung 
Foundation 2003).
Within the UK, 44% of COPD patients were found to be 
below retirement age: because of the condition, 24% were 
completely prevented from working. 5% of patients’ carers 
missed work. Around 12 days were missed from work, per 
patient per year. Productivity costs were found to be almost 
equivalent in size to direct costs; imposing an additional 
£820 (  = 1213) per patient per year upon the economy 
(Britton 2003).
Whilst productivity costs can represent a considerable 
burden on both the individual and on society, their use in 
cost effectiveness analyses is an area of controversy. This 
is partly due to methodological uncertainty concerning the 
appropriate method of measuring productivity losses, espe-
cially where signiﬁ  cant unemployment is evident (Sculpher 
2001). The US Panel on cost-effectiveness analysis recom-
mends a societal perspective which can include productivity 
losses (Gold et al 1996). By contrast, the National Institute 
for Health and Clinical Excellence in England and Wales 
limits its perspective to the health service and personal 
social services perspective and explicitly excludes the use 
of productivity costs in its evaluations.
Introduction to economic 
evaluation
Economic evaluation methodology has developed signiﬁ  -
cantly over recent years. In this section, we present some 
of the key concepts within economic evaluation. First, we 
provide an overview of economic evaluation and the various 
types that are often used. Second, we cover the evaluative 
process and describe important characteristics that should 
be conceptualized within each study: the perspective of the 
study and costs, the timeframe of the analysis, the use of 
appropriate comparators and outcome measures, the impor-
tance of accounting for uncertainty and issues surrounding 
industrial sponsorship.
Economic evaluation: an overview
Economic evaluations are used to assist decision makers in 
allocating scarce resources. Within health care, the overall 
objective is often considered to be to maximize the health 
of a given population, subject to the budget constraint for 
health care.
Many countries around the world now include a role for 
the incorporation of economic evidence into the decision 
making process for health, including many European coun-
tries, Australia and Canada (ISPOR 2007). In England and 
Wales, the relevant decision making agency is the National 
Institute for Health and Clinical Excellence (NICE) who are International Journal of COPD 2008:3(1) 75
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an organization independent from Government, responsible 
for providing guidance on the use of health technologies and 
the implementation of public health programs.
In the process of developing guidance, NICE brings 
together all the available clinical and economic evidence in 
order to decide whether the adoption of the technology (drug 
or treatment) represents good value for the NHS (National 
Institute of Health and Clinical Excellence 2005).
Types of economic evaluation
An economic evaluation can either be a cost effective-
ness, cost utility analysis, cost minimisation or cost beneﬁ  t 
analysis.
A cost beneﬁ  t analysis measures the value of an inter-
vention by a monetary value such as the dollar, or the Euro, 
and compares it to the costs of providing the treatment. The 
decision criteria as to whether or not to adopt the technology 
is based upon whether the beneﬁ  ts are greater than the costs. 
Where the alternatives under consideration have equal beneﬁ  t 
or effect, then it is possible to choose the optimal treatment 
based only upon their cost; this method is known as cost 
minimization. However, this scenario occurs infrequently 
because more often than not, different treatments will cause 
different effect and unless this is the case, cost minimization 
is inappropriate (Briggs and O’Brien 2001). More useful are 
cost effectiveness and cost utility analyses, which allow a 
full economic evaluation to take place where both the costs 
and outcomes are analyzed. The main difference between 
them lies in the outcome measure. Cost effectiveness studies 
present results in terms of natural units such as the cost per 
exacerbation avoided (Oostenbrink et al 2005), and improve-
ment in health status (Jones and Wilson 2003). A cost utility 
evaluation identiﬁ  es the cost per unit of utility (usually the 
Quality Adjusted Life Year [QALY]). Utilities and the QALY 
concept are described in detail below.
The decision making framework
The outcome measure(s) and corresponding type of economic 
evaluation, should be based upon the aim and intended use 
of the evaluation. Because of the outcome measures used 
within a cost effectiveness analysis, these studies can but 
inform the efﬁ  cient use of resources within COPD care. In 
order to inform the choice of whether to allocate more health 
care resources to the treatment of COPD compared to other 
disease areas, a generic outcome – a cost utility analysis – is 
required as this enables a comparison both within and across 
disease areas to be made. Indeed both NICE and the US Panel 
book recommend cost-utility analyses as the appropriate way 
to make comparative assessments of value for money within 
a health system (Gold et al 1996; Jones and Wilson 2003; 
National Institute for Clinical Excellence 2004).
Utilities and QALYs
A utility measure is a measure of the relative satisfaction 
– or quality of life – gained. In essence, a new treatment 
that leads to improved quality of life over a time period, 
compared to existing treatment, will generate greater utility 
than if the patient remained taking the existing treatment. 
The QALY quantiﬁ  es changes in utility over the life of 
the patient. The QALY has two components; quality and 
quantity of life.
In Figure 1 we can see that intervention 1 leads to higher 
quality of life (the line is above the other) and, greater life 
expectancy (quantity) than for intervention 2. The area 
between these lines represents the difference in the number   
of QALYs between the two treatments.
For example, a treatment may improve quality of life 
over the remainder of the patient’s life by 0.03, from 0.6 to 
0.63 and extend the life of the patient from 10 years to 11. 
This will give:
New treatment  Existing treatment
10 years at 0.63 = 6.3  10 years at 0.6 = 6
Plus one extra year of life = 0.63
QALYs = 6.93  QALYs = 6
The new treatment will add a total of 0.93 QALYs 
compared with the existing treatment. The QALY is by far 
the most accepted health-related utility measure and is the 
preferred outcome measure in many countries including 
Canada, New Zealand, Sweden, England and Wales, the 
Netherlands, and the US (ISPOR 2007).
ICERs
Using QALYs within an economic evaluation can allow 
treatments to be compared with one another across and 
within disease areas using a cost per QALY ratio, usually 
an Incremental Cost Effectiveness Ratio (ICER). ICERs 
allow comparison of the incremental costs (C) and incre-
mental beneﬁ  ts (B) of a new therapy (x) compared to the 
main comparator (y). The ICER is worked out using the 
simple formula:
  ICER
Cx Cy
Bx By
=
−
−
 
Using the previous example of a gain of 0.93 QALYs 
following treatment with the new drug and comparing this International Journal of COPD 2008:3(1) 76
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to the cost of the new treatment; £15,000 over the remainder 
of the patient’s life, compared to the cost of the existing 
treatment; £1000 gives an ICER of:
 
15,000 1000
£15,054
−
−
=
69 3 6 .
 
The resulting ICER describes the additional cost of an 
extra QALY by taking the new treatment rather than the 
existing one: the new treatment can provide one extra QALY 
for a cost of £15,054.
Threshold
Because the reimbursement of one treatment will displace 
monies spent from other treatments within the health system, 
it is important to ensure that the treatment reimbursed provides 
sufﬁ  cient value for money: we need a ‘guide price’ or a threshold 
from which we can decide whether or not any one treatment 
should be reimbursed by the health care system. In the UK, 
NICE’s documented threshold is said to be between £20,000 
and £30,000 per QALY, but this varies. It can be said that 
below £20,000 per QALY there is a high probability of the 
technology being accepted and that above £30,000 per QALY 
there is less chance of the technology being accepted. A more 
detailed discussion of relevant thresholds, including why a 
single threshold is not an appropriate concept, has been dealt 
with elsewhere (Culyer et al 2007).
Study-speciﬁ  c characteristics
Characteristics of health economic evaluations are outlined 
in this section in order to provide a foundation for the critical 
appraisal of studies.
Perspective and costs
The choice of perspective depends upon the target audience 
for the study (Philips et al 2006). There are several perspec-
tives: a speciﬁ  c provider/provider institution (ie, the National 
Health Service [NHS]), the patient/patient group, a third party 
payer (ie, an insurer) or the perspective of society (Drummond 
et al 2005). The perspective used will determine the costs 
employed and these must be appropriate and as comprehensive 
as required. A societal perspective would typically include 
productivity loss due to absence from/inability to work: a study 
from the perspective of a third party payer would not. NICE 
prefer the perspective of the NHS in their decision making 
process. It is often argued however, that economic studies for 
COPD should include all relevant costs associated with the ill-
ness (Sullivan 2003) and several countries – including Sweden 
and the Netherlands – suggest a societal perspective.
Study design
A study based upon a single source generally has patient 
level data and relies solely upon the results generated from 
that source to provide values for relative treatment effects, 
resource use, baseline characteristics, health outcomes and 
costs. Conversely, model-based evaluations usually incorpo-
rate data from a wide range of sources including: clinical and 
observational trials, burden of disease studies, epidemiologic 
and natural history studies.
Patient group
An economic evaluation can use efﬁ  cacy results from either, 
the whole population of interest or of different subgroups 
(ie, disease severity, age) within this population. It is 
important to consider any subgroups in order to permit, 
where evidence allows, the identiﬁ  cation of any speciﬁ  c 
group of patients to whom the technology is particularly 
cost-effective.
Timeframe of the analysis
Economic evaluations attached to clinical trials are naturally 
constrained by the timeframe of the trial to which they are 
connected. Decision analytic models have an advantage in 
that through applying adequate and transparent assump-
tions, the results can be extrapolated into the future, up to 
a lifetime timeframe. The deﬁ  nition of the timeframe of a 
study is crucial because the full beneﬁ  t of treatment may 
not occur within the period of the trial: the timeframe of the 
model should extend far enough into the future so that the 
key differences between the comparators in the analysis can 
be established (Philips et al 2006).
Figure 1 QALY’s.
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“There is no natural interpretation for life-years gained 
during a ﬁ  nite period of time, and the CE ratios that result 
from using different time horizons, such as one year and 
ﬁ  ve years, cannot be compared in any meaningful way … 
researchers who truncate their analyses have made, perhaps 
unwittingly, the implausible alternative assumption that study 
subjects experience neither the costs nor the beneﬁ  ts of living 
beyond the period of study” (Garber 2000 p191–2).
Comparators
Drummond deﬁ  nes economic evaluation as “the comparative 
analysis of alternative courses of action in terms of both their 
costs and consequences” (Drummond et al 2005 p 9). The 
comparative nature of economic analysis is all important 
since the use of an inappropriate comparator can bias an 
analysis and render it worthless for decision making. Most 
published guidelines for economic evaluations assert that 
the comparator of interest is current treatment (Drummond 
and Sculpher 2005). However, as the primary endpoint of 
RCTs which feed the economic evaluation with the clinical 
effectiveness data is drug registration, trials often provide the 
relative treatment effect compared to placebo only and this 
has been highlighted as a potentially fundamental problem 
of conducting economic analyses alongside clinical trials 
(Sculpher et al 2006).
Outcome measures and presentation of results
Whilst outcome measures should represent the aim of treat-
ment; to prevent and control symptoms, reduce the frequency 
and severity of exacerbations, improve health status and 
improve exercise tolerance (GOLD 2006), in order to make 
resource allocation decisions across disease areas, a generic 
form of outcome measure such as the QALY is required. 
Presenting cost-effectiveness analysis in natural units, such 
as cost per exacerbation avoided, will potentially limit the 
scope for decision making on the efﬁ  cient allocation of 
resources within COPD.
Handling of uncertainty
Uncertainty exists around all economic evaluations: there are 
uncertainties about the inputs into the study, and additionally, 
for decision analytic models, around the design of the 
study and any extrapolation of the results into the future. 
Where studies are undertaken within patient level data, a 
statistical analysis of the data will be possible allowing 
the use of conﬁ  dence intervals around cost-effectiveness 
results to summarize uncertainty. If the study uses a decision 
analytical modeling framework, sensitivity analysis, ideally 
probabilistic should be employed (Claxton et al 2005); this 
allows the combined uncertainty of all the parameters in 
the model to be included (Briggs 2002), by using the full 
probability distributions of each input into the model, rather 
than just the point estimates. A number of best practice 
guidelines (eg, the BMJ, NICE and US Panel) state that 
the uncertainty surrounding estimates of cost effectiveness 
needs to be explored when presenting economic evaluation 
results (National Institute for Clinical Excellence 2004). 
Probabilistic sensitivity analysis is now a formal requirement 
for cost effectiveness models submitted to NICE (National 
Institute for Clinical Excellence 2004).
Sponsorship
Industry sponsored studies represent a major source of 
funding for economic evaluations; however, concerns have 
been raised regarding potential biases arising as a result of 
this alliance. Studies have found an association between 
pharmaceutical sponsorship and the probability of a favorable 
result (Friedman 1999; Baker et al 2003; Bell et al 2006).
Pharmacoeconomics of COPD 
treatments
This section reviews the published literature on pharmaco-
economic assessments of treatments for COPD and uses the 
characteristics of studies identiﬁ  ed in the previous section 
to structure the review. The section begins with the search 
strategy and then we summarize the economic evaluations 
found from the search, categorized naturally into two: studies 
based on clinical trial or observational data alone and those 
based on a decision analytic model.
Study identiﬁ  cation
Search strategy
Four databases were used to search the literature: MEDLINE, 
EMBASE, the Centre for Reviews and Dissemination (CRD) 
and the Health Economics Evaluations Database (HEED) 
and restricted from 1990 until 2007. The search strategy 
was designed for MEDLINE and also applied to EMBASE. 
Included terms were: “Lung diseases, obstructive/ or bronchitis/ 
or pulmonary disease, chronic obstructive” or “COPD”, and 
“costs and cost analysis”/ or “cost beneﬁ  t analysis”/ or “cost 
of illness”/ or “health care costs”/ or “health expenditures” 
and “quality adjusted life years/ or cost utility” or “health adj4 
utilization” or “economic$ or economics, Pharmaceutical.”
For CRD and HEED—where this type of search strategy is 
not possible to apply—“cost” or “effectiveness” and “chronic” 
or “COPD” and the names of the individual drugs were used: 
“Fluticasone”, “Salbutamol”, “Ipratropium”, “Formoterol”, International Journal of COPD 2008:3(1) 78
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“Tiotropium” etc. MEDLINE gave 732 hits; EMBASE = 159; 
CRD = 235 and HEED = 53. Removing duplicates, a total of 
918 papers were found (March 2007). Reference lists from 
key papers were also searched for studies and papers: relevant 
papers were selected by ﬁ  rst reviewing the abstracts and then if 
deemed appropriate, the papers were obtained. Papers satisfy-
ing the inclusion and exclusion criteria were selected. Inclusion 
criteria were: economic evaluations of pharmacotherapy for 
COPD and in the English language. Exclusion criteria included 
papers where the focus was upon: cost alone, antibiotics or 
nonpharmacotherapy treatments. Fifteen pharmacoeconomic 
evaluations of COPD were identiﬁ  ed.
Table 3 provides a concise summary of the features of the 
economic evaluations, including the type of study, the main 
outcomes measures used and the design of the study.
The majority of studies identiﬁ  ed were conducted along-
side clinical trials (9/15); one used an observational study 
and ﬁ  ve a decision analytic model. Evaluations were either 
cost utility analyses (5/15) or cost effectiveness analyses 
(10/15). All the cost utility analysis studies used the QALY 
as an outcome measure. Along with the QALY, the main 
outcome measures were survival, reduction in exacerbations, 
improvement in SGRQ and improvement in FEV1.
Review of the clinical trial papers 
and the observational study
The key results from the nine randomized controlled trial 
studies and observational study are displayed in Table 4 and 
are described more fully within this section.
Perspective
Three different perspectives were used: the provider (ie, the 
NHS) (Ayres et al 2003; Briggs et al 2006) , societal (Ayres 
et al 2003; Oostenbrink et al 2004) and the payer (Hogan 
et al 2003; Jones and Wilson 2003; Gagnon et al 2005; 
Lofdahl et al 2005). In two cases no reference to perspective 
was made (Friedman 1999; van den Boom 2001).
Patient group
In order to compare patient severity for COPD, we con-
verted the information given into groups in line with the 
GOLD classiﬁ  cations. However, often scarce reporting 
within some papers around inclusion and exclusion criteria 
as well as heterogeneous classiﬁ  cations made it difﬁ  cult 
to convert accurately the disease severities into the GOLD 
classifications. All studies seemed to include severe 
COPD patients: most focusing upon moderate to severe 
(Rutten-van Molken et al 1995; Friedman 1999; Ayres 
et al 2003; Oostenbrink et al 2004; Briggs et al 2006). The 
observational study had COPD patients in each severity 
category as did Van den Boom’s. No reference to patient 
severity was made in Hogan’s paper and so the original 
trial publication had to be searched for this information 
(Dahl et al 2001).
Patient numbers and duration of the study
Patient numbers in each of the studies varied substantially 
from 74 participants (van den Boom 2001) to 1067 
(Friedman 1999). Most tended to have upwards of 500 
Table 3 Summary of COPD economic evaluations
Note: aReferring to a clinically meaningful change in each of these parameters, eg, some authors use a four point change on the SGRQ to mean a clinically signiﬁ  cant change.
 Authors CUA CEA
Clinical
trial
Observ
ational
Markov
model
FEV1
a Exacerb
ationsa
SGRQa Surviv
ala QALY
Ayres (2003)
Briggs (2006)
Friedman (1999)
Gagnon (2005)
Hogan (2003)
Jones (2003)
Jubran (1993)
Lofdahl (2005)
Maniadakis (2006)
Oostenbrink (2004)
Oostenbrink (2005)
Rutten-van Molken (1995)
Sin (2004)
Spencer (2005)
Van den Boom (2001)
Type Study design Outcome measuresInternational Journal of COPD 2008:3(1) 79
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participant, usually equally distributed between the 
treatment arms.
The shortest study durations were 3 months each 
(Friedman 1999; Hogan et al 2003), three were 12 months 
and the longest reported studies were 36 months (Gagnon 
et al 2005; Briggs et al 2006).
Comparators
Perhaps due to the very nature of the RCT and the complexi-
ties that doing so would demand, none of these studies used 
the preferred comparator of ‘current treatment’. Placebo 
was a comparator in seven out of the ten studies. In four out 
of the ten studies, the main point of interest was the cost 
effectiveness of a combined drug compared to its component 
parts and sometimes placebo. (Friedman 1999; Gagnon et al 
2005; Lofdahl et al 2005; Rutten-van Molken et al 1995). 
For example, Lofdahl investigated the cost effectiveness 
of placebo, Budesonide, Formoterol and the combination 
Budesonide and Formoterol. Oostenbrink measured the 
effects of replacing the short acting anticholinergic, Ipratro-
pium with the long acting equivalent, Tiotropium. Where two 
different dosages were examined, the dominated treatment 
was dropped from further study (Hogan et al 2003; Jones 
and Wilson 2003).
For the purposes of drug efficacy, these trials are 
perfectly acceptable. A problem arises when establishing 
cost effectiveness: where, as previously described, we use 
incremental effects and beneﬁ  ts arising from treatment 
compared to the alternative. However, if the comparator 
is not a real life existing/usual treatment or mix of treat-
ments, the results have little value for the decision maker 
to base a decision.
Outcome and outcome measures
A wide range of outcome measures are used within the ten 
studies. As previously described, some of the most com-
mon measures were QALYs, survival, change in SGRQ, 
and reduction in number of exacerbations and improvement 
in FEV1. In addition to this there were others, including: 
proportion of patients remaining free of exacerbations after 
six months (Ayres et al 2003), number of symptom free 
nights (Jones and Wilson 2003), a daytime symptom card of 
less than 2 (Jones and Wilson 2003), avoided exacerbation 
(Lofdahl et al 2005; Oostenbrink et al 2004) and improve-
ment in dyspnea (Oostenbrink et al 2004). Only two of the 
studies used QALYs (one derived QALYs through the SF-
36 [Briggs et al 2006] and the other through the HUI [van 
den Boom 2001]); an important measure from the point of 
view of the decision maker in resource allocation decisions 
across disease areas.
Results
All of these studies report a favorable outcome compared 
to the comparator(s): six found the study drug cost effec-
tive compared with the comparator(s) (van den Boom 
2001; Ayres et al 2003; Oostenbrink et al 2004; Gagnon 
et al 2005; Lofdahl et al 2005; Briggs et al 2006). The 
remaining four reported improvements in outcome associ-
ated with the study drug compared to the comparator(s) 
(Friedman 1999; Hogan et al 2003; Jones and Wilson 2003; 
Rutten-van Molken et al 1995). We believe that whilst 
the conclusions to come out of these studies may be valid 
within the context of the study, because of methodological 
gaps identiﬁ  ed above in all of these studies, whether that 
be outcome measures employed, perspective, interventions 
considered, patient group etc, their use within a decision 
making context – in which their primary purpose lies – is 
strictly limited.
Handling of uncertainty
Four of the studies used probabilistic sensitivity analysis 
(Oostenbrink et al 2004; Gagnon et al 2005; Lofdahl et al 
2005; Briggs et al 2006). Two studies used univariate sen-
sitivity analysis around the underlying assumptions such as 
adjusting the value for the cost per day (Ayres et al 2003) 
and inflating/deflating the cost of treatment drugs and 
rescue medication by 50% (Hogan et al 2003). Four made 
no mention of the uncertainty surrounding the economic 
evaluation (Rutten-van Molken et al 1995; Friedman 1999; 
van den Boom 2001; Jones and Wilson 2003). Uncertainty 
into the inputs into the model inherently exists, ie costs and 
effects. In order to account for this, a sensitivity analysis 
should be conducted in order to ensure that this uncertainty 
is captured.
Sponsorship
Most of the papers were sponsored by industry: ﬁ  ve fully 
sponsored (Friedman 1999; Ayres 2003; Oostenbrink et al 
2004; Lofdahl et al 2005; Briggs et al 2006). The paper by 
Jones did not state any information on ﬁ  nancial support, 
though one of the authors was working for GlaxoSmithKline 
(GSK). Three papers were partially supported by the industry 
(Rutten-van Molken et al 1995; Hogan et al 2003; Gagnon 
et al 2005). GSK supported most of the studies (5/10), Boeh-
ringer Ingelheim (BI; 2/10) and AstraZeneca and Novartis 
sponsored one each.International Journal of COPD 2008:3(1) 82
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Review of the decision analytic models
In this section, we examine the ﬁ  ve studies that used a deci-
sion analytic model framework for the economic evaluation: 
we take each model individually and inspect the methodol-
ogy/characteristics employed and some of the inputs used. 
The studies are summarized in Table 5.
Jubran (1993)
The Jubran paper (1993) is the earliest example of an eco-
nomic model applied to COPD. The study compares the costs 
and cost effectiveness of Theophylline vs Ipratropium from a 
societal perspective; based on three observational data sets, 
totaling 600 people with a diagnosis of moderate to severe 
COPD in three US sites. Resource use was extracted from 
these data sets to include: the number and type of visits made, 
drug treatments, lab tests, consultations and toxic events. 
From this data, estimates for labor, nonlabor and overhead 
costs were made. The datasets were uneven in duration 
(Theophylline: 7.1 months and Ipratropium: 5.9 months) but 
the results were extrapolated to one year.
The model consists of 7 Markov states; Stable, Clinic 
visit, Consult, ER Visit, Hospital, Major toxicity, Minor 
toxicity. The model assumes that the patient is in one of 
these states at any one time and transitions between these 
states take place at the end of the one month cycle. There 
are 12 cycles in total.
No ICER was calculated since Ipratropium was found to 
be both less costly and more cost effective than Theophyl-
line. Univariate sensitivity analysis was used to represent the 
uncertainty around costs and probabilities into the model. 
The study was sponsored by BI.
Sin (2004)
A societal perspective was adopted by Sin and colleagues 
(2004) for his Markov Model which examined the effects of 
adding inhaled corticosteroids to treatment for three groups; 
all COPD patients; patients with stage 2 or 3 disease and stage 
3 disease. The model was three years in duration with twelve 
cycles; each cycle being three months in length. The model 
was split into three states according to disease severity, 1 being 
least severe and 3 most severe. A ﬁ  nal position of death was 
not stated as an explicit state, though was inferred.
Data from the third National Health and Nutritional 
Examination survey were used to estimate the proportion 
of patients in each state. All cause mortality was estimated 
from published data; risk increased subject to disease sever-
ity and varied between those treated with ICS vs those who 
were not.
Assumptions used in the model:
•  Lung function declines over time (11.75 ml per cycle), 
regardless of severity group. From these values, the prob-
ability of progressing to the next stage was calculated and 
applied to all groups.
•  Health status declines with severity: QALY values 
applied were: 1.00 for stage 1, 0.92 for stage 2 and 0.84 
for stage 3. From baseline, a reduction of 0.32 QALYs per 
exacerbation was applied to each stage and the estimated 
duration of effect was 1 week (mild), 2 weeks (moderate) 
and 4 weeks (severe).
•  The rate and severity of exacerbations increases according 
to COPD stage.
•  Taking corticosteroids reduces the risk of all types of 
exacerbations by 30%.
Whilst the viewpoint was that of society, only direct 
marginal costs were included within the analysis and an 
estimation of the productivity costs associated with work 
loss during exacerbations for those 65 years or younger was 
only conducted during a secondary analysis.
Sin found that treatment was cost effective when given 
to patients with stage 2 or 3 disease. Probabilistic sensitivity 
analysis was performed to account for the uncertainty around 
the inputs of the model.
Oostenbrink (2005)
Oostenbrink et al (2005) designed this one year Markov 
model around disease severity states (moderate, severe and 
very severe) and exacerbations (severe) in order to examine 
the effects of substituting Ipratropium with Tiotropium in 
the Netherlands and in Canada. The model did not include 
a mild state or a death state.
Effectiveness data for the Tiotropium arm was based on 
data from six randomized controlled trials and for the Sal-
meterol and Ipratropium arms, from the relative difference to 
Tiotropium seen during the individual trials. In total, clinical 
trial data from 1876 people was used within the analysis. For 
the Netherlands, costs were mainly derived from an economic 
evaluation on resource use that was piggybacked onto the 
Ipratropium trials. For Canada, costs were estimated from 
an observational study.
Assumptions used in the modeling:
•  The length of the ﬁ  rst cycle was 8 days and all subse-
quent cycles were one month. Only one exacerbation was 
allowed during any one cycle. Transitions between states 
were assumed to take place halfway through the model.
•  Treatment was assumed to affect the transition prob-
abilities; the average Ipratropium patient was found to International Journal of COPD 2008:3(1) 83
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have a probability of 2.7 times more than the average 
Tiotropium for movement from a moderate to severe 
state (in the Sin model, the treatment was not assumed to 
affect these probabilities, compared to no treatment).
•  Mean EQ-5D index scores used were: moderate = 0.755; 
severe = 0.748 and very severe = 0.549. During a cycle 
in which an exacerbation occurs, utility is assumed to 
decrease (for the whole cycle) by 15% for a nonsevere 
exacerbation and 50% for a severe exacerbation.
In the Netherlands and in Canada, Tiotropium was found 
to be associated with maximum expected net beneﬁ  t for 
plausible values of the ceiling ratio.
In order to account for the uncertainties in the evaluation, 
Oostenbrink used probabilistic sensitivity analysis to test for 
the robustness of the result to changes in the baseline values 
of the model eg utility values and the baseline distribution 
of patients assigned to each state. The study was sponsored 
by BI.
Spencer (2005)
Spencer and colleagues’ model (Spencer et al 2005) employ 
a Markov model in order to compare the cost effectiveness of 
the combination drug Salmeterol/Fluticasone, to usual care. 
The model has four mutually exclusive states: mild, moderate, 
severe and death, (which are equivalent to the GOLD stages: 
mild/moderate, severe and very severe). The cycles of the model 
were 3 months in duration and a maximum time horizon of 
25 years applied. Baseline values for the model were sourced 
from GSK clinical trial data (TRISTAN), published medical 
literature and from expert opinion. It was not transparent where 
the cost data came from, though references to published medical 
literature, clinical trial data and expert opinion were made.
Assumptions used in the modelling:
•  Transition probabilities between the states were calcu-
lated from a published formula. Smokers and ex-smokers 
were found to have increased FEV1 rates of decline: 
62 ml and 31ml respectively.
•  Estimates of health status by disease stage were mild: 
0.81, moderate: 0.72 and severe: 0.67.
•  Exacerbations were split into major and minor, (major 
being those requiring hospital treatment) and the esti-
mated frequency of each was calculated, for every health 
state. Using the EQ-5D score, estimates for health status 
during an exacerbation were obtained from 27 respira-
tory physicians who completed the questionnaire from 
the perspective of their patients. Utility weights were as 
follows: For a minor exacerbation health status dropped 
to 0.61 (mild), 0.61 (moderate) and 0.05 (severe). For a 
major exacerbation, health status fell to −0.26 regardless 
of disease severity.
•  The study assumes a nonlinear recovery from the ‘low 
point’ to a position of 0.03 utility points below those of 
others in the study that have not had an exacerbation.
•  Treatment was assumed to affect the risk of an exacerba-
tion, the risk of disease progression, risk of mortality and 
the patients’ health status.
The paper concludes that by adding a long acting B2 
agonist to an inhaled corticosteroid, this may represent a 
cost effective treatment in those patients who have a history 
of frequent exacerbations and poorly reversible COPD. 
A probabilistic sensitivity analysis was performed around 
the discount rate, exacerbation rate and the mortality beneﬁ  t. 
The study was sponsored by GSK.
Maniadakis (2006)
This model, adapted from Oostenbrink’s model to a Greek 
setting, sought to establish the cost effectiveness of Tiotro-
pium compared with Salmeterol, from the perspective of the 
Greek NHS (Maniadakis et al 2006). Whilst Tiotropium was 
concluded to be cost effective, there was actually no statisti-
cally signiﬁ  cant difference found between the treatments. 
Probabilistic sensitivity analysis was performed around the 
baseline values. As with Oostenbrink’s paper, this too was 
ﬁ  nancially supported by BI.
Summary
From the descriptions of the decision analytic models, it 
is clear, excluding Jubran, that there are many similarities 
in the approach adopted. The four papers all used a utility 
measure in their analysis. The disease has been modeled 
using stages of the disease and at each stage; an exacerbation 
causes a drop in health related quality of life for the modeled 
patient. However, at the same time, there are differences 
concerning inputs into the model, some of which have been 
described elsewhere (Rutten-van Molken et al 2006). Table 6 
illustrates the differences between the papers by Sin, Oosten-
brink, and Spencer. The patients were grouped according to 
severity in line with those reported: FEV1   50% (GOLD 
moderate); 35%   FEV1  50% (approx GOLD severe); and 
FEV1   35% (approx GOLD very severe).
Differences between the values given for health state at 
each disease status differ dramatically between the papers 
eg, very severe: 0.55 (Oostenbrink) 0.84 (Sin) and 0.67 
(Spencer). In the same way, health state and duration of 
effect assigned to an exacerbation also differ: the reduction 
in health following a major exacerbation for a very severe International Journal of COPD 2008:3(1) 85
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patient was assessed to be 0.27 (one month) Oostenbrink, 
0.52 (one month) Sin and Spencer −0.26 (six months recov-
ery time).
In order to compare and utilise economic models in the 
future for COPD, work must be done it ensure that the correct 
methodology is applied and that appropriate and valid inputs 
are used to populate the model. Disparities in utility values 
and the effect upon health related quality of life both during 
and following an exacerbation need to be ironed out, and a 
common consensus sought through further research.
Discussion
The output of an economic evaluation is to inform and assist 
the decision maker in allocating scarce health care resources, 
but how far does the existing literature go in fulﬁ  lling this 
role?
Fundamental is the design of the study; RCT, observa-
tional study based or employing a decision analytic model: 
this decision is all-important. For an economic evaluation to 
provide us with results suitable for applying to a wider popu-
lation, the study should be internally and externally valid. 
Internal validity refers to the results of the study being true for 
the population under study (randomized controlled trials are 
regarded as the gold standard for efﬁ  cacy and effectiveness 
data because of the way in which the trials are conducted 
results in a high level of internal validity, producing unbiased 
estimates of treatment effects (Cook et al 2004)). External 
validity on the other hand refers to the results of the study 
being generalizable to a wider population. Economic evalua-
tions based entirely upon randomized controlled trials (RCTs: 
with tight inclusion and exclusion criteria) may have limited 
generalizabilty to a wider population which may “seriously 
restrict their relevance for policy making” (Baltussen et al 
1999 p 450). The validity of observational studies depends 
upon the extent to which the component study populations 
are equivalent, the conclusions of such studies may need 
supporting evidence from RCTs. It is further suggested 
that modeling and the addition of observational data can 
enhance the external validity of the cost effectiveness study 
based on RCTs (Baltussen et al 1999). In addition, within 
an RCT based study, efﬁ  cacy data is conﬁ  ned to the length 
of the trial. To be of most value to clinicians and health care 
funding agencies, the costs and beneﬁ  ts should be considered 
over a period that reﬂ  ects the longevity of the effects of the 
intervention. (Halpin 2006). This may be much longer than 
the trial itself; consequently, a cost effectiveness ratio based 
solely upon the duration of the trial may fail to capture the 
longer-term effects of treatment, such as extended life of 
study patients. Indeed there is current debate around the 
impact on survival of some treatments for COPD: recent evi-
dence from trials such as ISOLDE, TRISTAN, and TORCH 
has suggested a survival effect of therapy in COPD patients 
following treatment with the combination product Salmeterol 
and Fluticasone (TORCH). Incorporation of this effect into 
economic evaluations by using decision-analytic models to 
extrapolate from trial evidence may result in dramatic reduc-
tions of the resulting incremental cost effectiveness ratios 
(Sin et al 2004; Spencer et al 2005).
We see a clear and continuing role for the use of decision 
analytic models in economic evaluation of COPD therapies. 
A modeling framework can produce externally valid studies 
(based on internally valid evidence of treatment effects), 
capturing the long-term effects of treatment, thereby being 
useful in assisting the decision maker in allocating resources. 
Economic models in all their forms need to be methodologi-
cally sound, have relevant and valid inputs and to be well 
described and explained. In addition, sensitivity analysis 
needs to be executed with care, distributions around the 
inputs explained and reasoned, and extrapolation needs to 
be adopted and presented with caution. As we have seen in 
this paper, within pharmacoeconomics for COPD, there are 
twice as many economic evaluations alongside clinical trials 
or observational studies (10) compared to those based on 
decision analytic modeling (5). Economic evaluations in the 
future should ideally be based on modeling or on sufﬁ  ciently 
long study durations so as to capture the relevant costs and 
effects to enable the analysis to deliver results that can be 
used by decision makers.
Results of economic evaluations are likely to vary 
according to the perspective employed. Perspective should 
be clearly stated within the paper and the results presented 
Table 6 Health status according to disease severity and impact 
of an exacerbation (utilities)
      Moderate  Severe  Very
       Severe
Oostenbrink Baseline  0.76  0.75  0.55
(2005)  ↓ to (minor exac)  0.64  0.64  0.47
   ↓ to (major exac)  0.38  0.37  0.27
   Duration of effect  1 month  1 month  1 month
Sin (2004)  Baseline  1.00  0.92  0.84
   ↓ to (exac)  0.68  0.60  0.52
   Duration of effect  1 week  2 weeks  4 weeks
Spencer Baseline  0.81  0.72 0.67
(2005)  ↓ to (minor exac)  0.61  0.61  0.05
   ↓ to (major exac)  −0.26  −0.26  −0.26
   Duration of effect  Recovery over six monthsInternational Journal of COPD 2008:3(1) 86
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should be based upon the adopted perspective. Three 
evaluations did not mention perspective (Friedman 1999; 
van den Boom 2001; Oostenbrink et al 2005).
Most economic evaluations used, as comparators, one 
or two drugs that are currently available for treatment of 
COPD and 7/15 included placebo as one of the comparators. 
Only two studies (Sin et al 2004; Spencer et al 2005) 
include a range of relevant alternatives, including existing 
treatment. Decision makers need to know the full impact of 
the introduction of a new therapy to a disease or treatment 
area and this can best be achieved by using usual care 
as a comparator. “Decisions on cost effectiveness should 
be based on the comparison of a new intervention with 
current practice, rather than with a placebo” (Claxton et al 
2002 p 711).
A wide range of outcome measures have been used in 
economic evaluations of COPD. Although it may be the 
case that “…it is neither known nor generally agreed which 
outcomes are most relevant” (Gross 2004 p 41); a range of 
outcome measures causes a problem for the decision maker, 
who is faced with the problem of making a judgment based 
on disparate results that are not directly comparable. For 
example, to what extent is the avoidance of a certain number of 
exacerbations equivalent to an average improvement in FEV1? 
The economists’ solution is the QALY (described above), 
which combines the effects of treatment into a single measure 
which can be compared both within and across disease areas. 
Within the England and Wales, NICE have stated “the QALY 
is considered to be the most appropriate generic measure of 
health beneﬁ  t that reﬂ  ects both mortality and HRQL” (National 
Institute for Clinical Excellence 2004 p 22). The QALY is a 
particularly useful outcome measure for economic evaluations 
of interventions in COPD, as treatment for which may result 
in both survival and quality of life gains.
The strength of cost utility analyses based on QALYs 
depends upon the robustness of the derivation of the utility 
values. In each of the three modeling studies that used 
QALYs, the utility weights applied to different COPD states 
and to the impact of exacerbations varied quite considerably 
as previously shown in Table 6. The most likely reason 
behind these differences in utility values is the different 
methods of elicitation (and the population surveyed). NICE 
suggests utilities should be derived using a choice based 
method such as the time trade off or the standard gamble, 
applied to a representative sample of the public. The decre-
ment in utility (from baseline) associated with each exacer-
bation and length of time to which this decrease is applied 
(duration of exacerbation), differs considerably between 
studies. It would be valuable to undertake further research 
into the derivation of utility values for COPD patients, and in 
particular, the recovery time and drop in health related quality 
of life, both during the exacerbation and recovery following 
an exacerbation. Further research needs to be conducted 
within this area in order to harmonize utility values.
Four out of the ﬁ  fteen studies did not consider uncer-
tainty within their analyses, three used one way, eight used 
probabilistic sensitivity analysis. An assessment of uncer-
tainty should be included within an economic evaluation, to 
reﬂ  ect uncertainty in the composition of the study population 
and in the cost and health outcomes results obtained from 
the study. In the case of modeling studies, there are further 
uncertainties, such as in the design of the model itself and the 
extrapolation of study data to a time horizon that extends the 
life of the trial. Probabilistic sensitivity analysis is preferred 
for assessing uncertainty in modeled economic evaluations 
because it allows the combined uncertainty surrounding all 
of the parameters within the model to be assessed (Briggs 
2002).
All, bar one of the 15 studies have been sponsored to 
some extent by the pharmaceutical industry and the study 
drugs in each of these papers were reported to have a favor-
able cost-effectiveness result. Concerns about the outcomes 
of these studies, because of issues around: selection of study 
design, patient population and the potential for bias in the out-
come and in the publication, are often raised. Nevertheless, 
the industry is an important provider of cost effectiveness 
data, especially to support submission for reimbursement 
in particular countries. In addition, the industry, because 
of tight regulating standards, may pay closer attention to 
quality control than academic institutes. Whatever the pro’s 
and con’s are, industry ﬁ  nanced studies will continue to be 
a valuable source of data, however there is a gap for non-
industry sponsored evaluations in COPD and efforts should 
be made to provide the resources necessary in order to support 
nonindustry bodies in producing such studies.
Conclusion
This paper has provided an overview of the burden of ill-
ness and costs associated with COPD, explained economic 
evaluation, reviewed and critically appraised the published 
economic evaluation of therapies in COPD and has discussed 
the use of existing economic evaluations in informing 
and assisting the decision maker to allocate scarce health 
care resources.
It has been suggested that consistency between evaluations 
is necessary in order for comparisons to be made between International Journal of COPD 2008:3(1) 87
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different treatments over time (National Institute for Clinical 
Excellence 2004). Whilst all the ﬁ  fteen economic evaluations 
report beneﬁ  ts of the main study drug; either that is cost effec-
tive, or that, compared to the alternative under consideration, 
the treatment represented signiﬁ  cant improvements in the 
measured outcome. As previously reported in relation to early 
economic evaluations for COPD (Ruchlin and Dasbach 2001), 
there is little consistency between the studies methodologi-
cally. Differences in study design, comparators, interventions, 
outcome measures and the analysis of uncertainty make 
meaningful comparison between the studies very difﬁ  cult. 
Indeed direct comparisons between treatments for COPD are 
not available, precisely because of this issue.
However, for the decision maker and for the clinician, 
it is of utmost importance that interventions are directly 
comparable. Decisions must be made as to the most suitable 
treatment; informed decisions, based upon and supported by 
all available knowledge and evidence of substitute or alterna-
tive treatments are most likely to be appropriate.
Efforts should be made for future clinical trials and 
economic studies to harmonize study design and methods, 
particularly towards adopting a universal modeling frame-
work, using current treatment as comparator and adopting an 
effectiveness measure such as the QALY in order to produce 
results that are comparable across interventions and disease 
areas, and that are useful to a decision maker.
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